Scinai Licenses IL-17 Antibody Technology from Max Planck, Gottingen Medical Center
On June 4, 2023, BiondVax Pharmaceuticals Ltd., which trades as SCNI, entered an exclusive worldwide license to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) from Max-Planck-Innovation GmbH and University Medical Center Gottingen. The company agreed to issue 17,000 American Depository Shares to the counterparties and to owe milestone payments and royalties on net sales, and the license will terminate if an IND is not submitted by the stated deadlines.
Key points
- 17,000 American Depository Shares to be issued to the counterparties within 45 days of June 4, 2023
- Recipients agreed not to sell the ADSs until June 4, 2024
- IND submission deadline of June 30, 2025, with a possible extension of 12 months per EUR 500,000 payment
- License terminates prior to December 31, 2026 if the IND deadline is not met
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 08, 2023.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.